AFS-13-200-E 

February 22, 2013 

 Exemption No. 10690A 

 Regulatory Docket No. FAA-2013-0034 

Stacey Bechdolt, Esq. 

Director, Safety & Technical Affairs 

Regional Airline Association 

2025 M Street, NW., Suite 800 

Washington, DC 20036 

Mr. Douglas Mullen 

Assistant General Counsel 

Airlines for America 

1301 Pennsylvania Avenue, NW, Suite 1100 

Washington, DC 20004 

Mr. George Paul 

Director of Technical Services 

National Air Carrier Association 

1000 Wilson Boulevard, Suite 1700 

Arlington, VA 22209 

Dear Ms. Bechdolt: 

This letter is to inform you that we have granted your petition to amend Exemption 

No. 10690. It explains the basis for our decision, describes its effect, and lists the revised 

conditions and limitations. 

The Basis for Our Decision 

By letter dated February 1, 2013, you petitioned the Federal Aviation Administration (FAA) 

on behalf of Regional Airline Association (RAA) for an amendment to Exemption No. 10690. 

That exemption from § 121.803(c)(3) and Appendix A of part 121 of Title 14, Code of 

Federal Regulations (14 CFR) would provide relief from the requirement to include Atropine 
 2

in an Emergency Medical Kit (EMK). The amendment you request would change the name 

from Silver Airlines to Silver Airways 

In your petition, you indicate that there has been no change in the conditions and reasons 

relative to public interest and safety that were the basis for granting the original exemption. 

The FAA has determined that good cause exists for not publishing a summary of the petition 

in the Federal Register because the requested amendment to the exemption would not set a 

precedent, and any delay in acting on this petition would be detrimental to RAA. 

Our Decision 

Under the authority contained in 49 U.S.C. §§ 40113 and 44701, which the FAA 

Administrator has delegated to me, I hereby grant Regional Airline Association, Airlines for 

America, and National Air Carrier Association an exemption from 14 CFR § 121.803(c)(3) 

and Appendix A of part 121, to the extent necessary to relieve them from the requirement to 

carry two single dose ampules of Atropine 5cc injectable, in required on-board EMKs when, 

due to the nationwide shortage discussed herein, they are unable to procure these items for the 

kits, subject to the following revised conditions and limitations. 

Conditions and Limitations 

1. This exemption applies to the part 119 certificate holders authorized to conduct 

part 121 passenger carrying operations listed below. 

Air Transport International ExpressJet Republic Airlines 

Air Wisconsin Airlines 

Corp. 

GoJet Ryan International Airlines

Alaska Airlines Great Lakes Aviation Seaborne Airlines 

Allegiant Air Hawaiian Airlines, Inc. Shuttle America 

American Airlines Horizon Air Silver Airways 

American Eagle Island Air SkyWest Airlines, Inc. 

Atlas Air, Inc. JetBlue Airways Corp. Southwest Airlines, Inc. 

Cape Air Miami Air International Sun Country Airlines 

Chatauqua Airlines National Airlines Trans States Airlines 

CommutAir National Air Cargo United Airlines, Inc. 

Compass Airlines Omni Air International US Airways, Inc. 

Delta Air Lines, Inc. Piedmont Airlines USA Jet Airlines 

Era Aviation Pinnacle Airlines, Inc. World Airways 

Everts Air Cargo PSA Airlines 

2. A copy of this exemption must be carried on board each aircraft operating with 

emergency medical kits that do not include Atropine as required by Appendix A of 

part 121. 
 3

3. The pilot in command must inform crewmembers that any emergency medical kits on 

board the aircraft may not contain Atropine as part of the pre-flight briefing. 

4. This exemption may be used for flights conducted outside of the United States. 

The Effect of Our Decision 

The termination date of Exemption No. 10690 remains January 31, 2014, unless sooner 

superseded or rescinded. 

Sincerely, 

/s/ 

Michael J. Zenkovich 

Acting Deputy Director, Flight Standards 

Service